Intravitreal fluocinolone acetonide implant (ILUVIEN®) for diabetic macular oedema: a literature review.
Horace F MassaAnindyt M NagarAthanasios VergadosPanagiotis DadoukisSudeshna PatraGeorgios D PanosPublished in: The Journal of international medical research (2018)
Diabetic macular oedema (DMO) is a common complication of diabetic retinopathy and may lead to severe visual loss. In this review, we describe the pathophysiology of DMO and review current therapeutic options such as macular laser photocoagulation, anti-vascular endothelial growth factor agents, and steroid implants with a focus on the new fluocinolone acetonide implant, ILUVIEN®. The results of the Fluocinolone Acetonide in Diabetic Macular Edema (FAME) studies are also presented together with the results of real-world studies to support the clinical use of ILUVIEN® in achieving efficient resolution of DMO and improving vision and macular anatomy in this challenging group of patients.
Keyphrases
- diabetic retinopathy
- optical coherence tomography
- vascular endothelial growth factor
- end stage renal disease
- type diabetes
- soft tissue
- ejection fraction
- newly diagnosed
- wound healing
- endothelial cells
- prognostic factors
- case report
- case control
- peritoneal dialysis
- early onset
- patient reported outcomes
- single molecule
- high speed
- high resolution
- drug induced